Premium
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation
Author(s) -
Younossi Zobair M.
Publication year - 2018
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.25003
Subject(s) - medicine , nonalcoholic steatohepatitis , liver transplantation , nonalcoholic fatty liver disease , gastroenterology , liver disease , fatty liver , transplantation , disease
Nonalcoholic fatty liver disease (NAFLD), a common cause of chronic liver disease (CLD), has a global prevalence of 25%.[1][Younossi ZM, 2016] Its progressive form, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplantation (LT) in the United States.[2][Wong RJ, 2015], [3][Goldberg D, 2017] As a result, specialty societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver, have developed guidance on the epidemiology, diagnosis, and treatment of NAFLD and NASH.[4][Chalasani N, 2012], [5][, 2016] Therefore, the transplant team must be well versed in the state of current knowledge about NAFLD and transplant‐specific issues for this increasingly important indication for LT. Liver Transplantation 24 166–170 2018 AASLD.